SCHEMBL24849935

SCHEMBL24849935

Cn1cc(-n2cc(C(=O)Nc3ccc(OC(F)(F)Cl)cc3)cc(Br)c2=O)cn1

nearest known ligand 0.50

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 20/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23091689 0.87 ABL1 (0.48) ABL1
SCHEMBL23091743 0.85 ABL1 (0.52) ABL1
SCHEMBL23091672 0.84 ABL1 (0.53) ABL1
SCHEMBL29687479 0.84 ABL1 (0.53) ABL1
SCHEMBL23091674 0.82 ABL1 (0.56) ABL1
SCHEMBL23091718 0.79 ABL1 (0.56) ABL1
SCHEMBL24850863 0.78 ABL1 (0.68) ABL1
SCHEMBL23091656 0.76 ABL1 (0.58) ABL1
SCHEMBL23091686 0.75 ABL1 (0.55) ABL1
SCHEMBL23091661 0.74 ABL1 (0.44) ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002346-A1 NEW COMPOUNDS AND METHODS BenevolentAl Bio Limited (GB) 2023-01-05 — — US disclosed
US-20230002346-A1 NEW COMPOUNDS AND METHODS BenevolentAl Bio Limited (GB) 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002346-A1 NEW COMPOUNDS AND METHODS ABL2, ABL1, ALK ABL1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback